FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1569205373> ?p ?o ?g. }

• W1569205373 endingPage "92" @default.
• W1569205373 startingPage "485" @default.
• W1569205373 abstract "We studied the accumulation of [3H]vinblastine (VLB) by lines of CCRF-CEM cultured human leukemic lymphoblasts that were either sensitive or resistant to the drug. Neither cell line metabolized VLB, nor selectively retained any radioactive impurities. There was an apparent instantaneous accumulation of VLB by cells of both lines, resulting in cell to medium ratios greater than 1.0 within 1 sec after drug addition. Experiments between 0 and 60 sec revealed that the presumed undirectional initial rate of VLB accumulation by resistant cells, termed CEM/VLB100, was about one-half that of sensitive CEM cells. In experiments carried out over 60 min, the VLB-resistant cells accumulated considerably less [3H]VLB than did the sensitive cells. Drug accumulation by both cell lines was temperature-sensitive, since incubation of cells at 4 degrees resulted in only minimal uptake beyond that observed at zero time. CEM/VLB100 cells retained less drug than did CEM cells, apparently because of a larger fraction of readily releasable VLB compared with CEM cells. The accumulation of VLB by either cell line was related in part to cellular levels of ATP. Although depletion of ATP was associated with decreased accumulation of VLB by CEM cells, it was related to enhanced drug accumulation by CEM/VLB100 cells. Restoration of ATP levels to near control values by addition of glucose also had opposite effects on the two cell lines, causing further accumulation of VLB by the sensitive line but leading to apparent drug efflux from the resistant line. Potentially competing substrates (VM-26, colchicine, daunorubicin, and doxorubicin) failed to block this glucose-mediated release of VLB from the CEM/VLB100 cells. In experiments with energy-depleted CEM/VLB100 cells preloaded with VLB and then incubated in drug-free medium, initial drug loss was shown to be independent of cellular metabolism, being roughly the same for both metabolically intact and metabolically depleted cells. Glucose (energy) was required only for subsequent release of what appeared to be a more tightly bound cell-associated fraction of VLB. Results of zero-time binding studies tended to confirm that VLB binding by resistant cells has two components, one requiring and the other not requiring metabolic energy. Differences in the proportions of these two components between the sensitive and resistant cells suggest a mechanism for resistance to VLB and similar compounds." @default.
• W1569205373 created "2016-06-24" @default.
• W1569205373 creator A5011797498 @default.
• W1569205373 creator A5050955474 @default.
• W1569205373 creator A5059498891 @default.
• W1569205373 date "1983-11-01" @default.
• W1569205373 modified "2023-09-23" @default.
• W1569205373 title "Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts." @default.
• W1569205373 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6579344" @default.
• W1569205373 hasPublicationYear "1983" @default.
• W1569205373 type Work @default.
• W1569205373 sameAs 1569205373 @default.
• W1569205373 citedByCount "38" @default.
• W1569205373 countsByYear W15692053732016 @default.
• W1569205373 crossrefType "journal-article" @default.
• W1569205373 hasAuthorship W1569205373A5011797498 @default.
• W1569205373 hasAuthorship W1569205373A5050955474 @default.
• W1569205373 hasAuthorship W1569205373A5059498891 @default.
• W1569205373 hasConcept C113842279 @default.
• W1569205373 hasConcept C12554922 @default.
• W1569205373 hasConcept C1491633281 @default.
• W1569205373 hasConcept C153911025 @default.
• W1569205373 hasConcept C185592680 @default.
• W1569205373 hasConcept C2776553716 @default.
• W1569205373 hasConcept C2776694085 @default.
• W1569205373 hasConcept C2776755627 @default.
• W1569205373 hasConcept C2777132456 @default.
• W1569205373 hasConcept C2779429289 @default.
• W1569205373 hasConcept C54355233 @default.
• W1569205373 hasConcept C55493867 @default.
• W1569205373 hasConcept C81885089 @default.
• W1569205373 hasConcept C86803240 @default.
• W1569205373 hasConceptScore W1569205373C113842279 @default.
• W1569205373 hasConceptScore W1569205373C12554922 @default.
• W1569205373 hasConceptScore W1569205373C1491633281 @default.
• W1569205373 hasConceptScore W1569205373C153911025 @default.
• W1569205373 hasConceptScore W1569205373C185592680 @default.
• W1569205373 hasConceptScore W1569205373C2776553716 @default.
• W1569205373 hasConceptScore W1569205373C2776694085 @default.
• W1569205373 hasConceptScore W1569205373C2776755627 @default.
• W1569205373 hasConceptScore W1569205373C2777132456 @default.
• W1569205373 hasConceptScore W1569205373C2779429289 @default.
• W1569205373 hasConceptScore W1569205373C54355233 @default.
• W1569205373 hasConceptScore W1569205373C55493867 @default.
• W1569205373 hasConceptScore W1569205373C81885089 @default.
• W1569205373 hasConceptScore W1569205373C86803240 @default.
• W1569205373 hasIssue "3" @default.
• W1569205373 hasLocation W15692053731 @default.
• W1569205373 hasOpenAccess W1569205373 @default.
• W1569205373 hasPrimaryLocation W15692053731 @default.
• W1569205373 hasRelatedWork W1986183450 @default.
• W1569205373 hasRelatedWork W2026492013 @default.
• W1569205373 hasRelatedWork W2095109963 @default.
• W1569205373 hasRelatedWork W2168793395 @default.
• W1569205373 hasRelatedWork W2171935960 @default.
• W1569205373 hasRelatedWork W2411576994 @default.
• W1569205373 hasRelatedWork W2413659186 @default.
• W1569205373 hasRelatedWork W2466139994 @default.
• W1569205373 hasRelatedWork W2481209781 @default.
• W1569205373 hasRelatedWork W3173324017 @default.
• W1569205373 hasVolume "24" @default.
• W1569205373 isParatext "false" @default.
• W1569205373 isRetracted "false" @default.
• W1569205373 magId "1569205373" @default.
• W1569205373 workType "article" @default.